Osteoarthritis: Structural Endpoints for the Development of Drugs

Issue Date: August 23, 2018
Issued by: Center for Biologics Evaluation and Research
Topic(s): Clinical – Medical
Status: Draft

Osteoarthritis: Structural Endpoints for the Development of Drugs

The purpose of his guidance is to assist sponsors who are developing drugs, devices, or 20 biological products (medical products) to treat the underlying pathophysiology and structural progression of osteoarthritis (OA).2 21

Download the Guidance Document

webmaster2026-08-05T19:01:20+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.